Key result
Current CKD treatments lack specific anti-fibrotic drugs, highlighting the need for emerging targeted therapies.
Why the study?
Current clinical treatments for CKD focus on primary diseases without specific drugs targeting renal fibrosis, and no drugs are available to reverse its complex pathogenesis.
This review provides a comprehensive overview of the pathogenesis of renal fibrosis and summarizes current and emerging anti-fibrotic therapies for chronic kidney disease.
No approved anti-fibrotic agents exist for CKD; leaves open targeted therapy development pending prospective trials.
Renal fibrosis is the common pathological basis for the progressive development of chronic kidney disease (CKD) caused by various etiologies. It is characterized by the persistent deposition of extracellular matrix, leading to renal tissue damage and impaired renal function, and ultimately progressing to kidney failure. Current clinical treatments for CKD mainly focus on managing the primary diseases, with no specific drugs targeting renal fibrosis. The pathogenesis of renal fibrosis is complex, and there are currently no drugs available to reverse it. A comprehensive overview of the pathogenesis of renal fibrosis, alongside a summary of current anti-fibrotic therapies, including some that are already used clinically to slow renal function progression, new drugs in clinical trials, and emerging targeted therapies, could provide new theoretical foundations and perspectives for the treatment of renal fibrosis.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2024) conducted a review in Renal fibrosis and chronic kidney disease. Anti-renal fibrosis drugs was evaluated. Current clinical treatments for chronic kidney disease lack specific drugs targeting renal fibrosis, highlighting the need for new anti-fibrotic therapies and emerging targeted treatments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: